Clinical trials: Advanced Colorectal Cancer
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma
- Trial name
- NCT02595931
- Testing
- Berzosertib, Biopsy Specimen, Biospecimen Collection
- Where
- 23 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Colon Cancer
Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
Neoadjuvant chemotherapy has been validated by several clinical studies to achieve preoperative downstaging and improve survival outcomes in patients with locally advanced colon cancer .
- Trial name
- NCT06790212
- Testing
- Ivonescimab, Oxaliplatin, Capecitabine
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT06124378
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Neoplasms, Stomach Neoplasm
Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
This study is a phase Ib, open label, multi-centre trial designed to estimate the Maximum Tolerated Dose (MTD) of lithium when combined with a standard chemotherapy regimen of oxaliplatin and capecitabine in patients with…
- Conditions
- Colorectal Neoplasms, Stomach Neoplasm, Esophageal Neoplasms
- Trial name
- Lithium (NCT03153280)
- Testing
- Lithium, Oxaliplatin, Capecitabine
- Where
- 2 sites in Ireland
- Volunteers
- 2 people
- Sponsor
- Cancer Trials Ireland
Colorectal Cancer
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
This phase II study will evaluate the efficacy of the combination of two monoclonal antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed after 1st line treatment with FOLFIRI Avastin or…
- Trial name
- NCT00681876
- Testing
- Irinotecan, Avastin, Erbitux
- Where
- 8 sites in Greece
- Volunteers
- 16 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Cancer
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer
The purpose of this study is to determine efficacy of SB injection in Colorectal Cancer.
- Trial name
- NCT01305980
- Testing
- SB injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- SBPharmaceutical IND, Co., LTD
Colorectal Cancer
Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can find and locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003543
- Testing
- monoclonal antibody A33, carmustine, fluorouracil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer
Post-Neoadjuvant Treatment MRI Based AI System to Predict pCR for Rectal Cancer
In this study, investigators seek for a better way to identify the potential pathologic complete response (pCR) patients form non-pCR patients with locally advanced rectal cancer (LARC), based on their post-neoadjuvant treatment…
- Trial name
- MR-AI-pCR (NCT04278274)
- Testing
- artificial intelligence prediction system, the radiologists
- Where
- 3 sites in China
- Volunteers
- 205 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cancer Colorectal
Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives
The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced…
- Trial name
- EDUCANCOLAGE (NCT03084133)
- Testing
- Therapeutic Education Strategy
- Where
- 8 sites in France
- Volunteers
- 68 people
- Sponsor
- University Hospital, Tours
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Colorectal Neoplasms, Colonic Neoplasms
Study Evaluating EKB-569 in Advanced Colorectal Cancer
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer.
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00072748
- Testing
- EKB-569
- Volunteers
- 63 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
This is a phase III, multi-center, double-blind randomized controlled trial assessing the efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined with PD-1 antibody Sintilimab for locally…
- Conditions
- Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer, Anal Cancer
- Trial name
- NCT05374252
- Testing
- PD-1 inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer